RBC Capital lowered the firm’s price target on Legend Biotech (LEGN) to $62 from $66 and keeps an Outperform rating on the shares after its Q4 results. The firm sees a significant disconnect between the share price and the fundamentals of the business, the analyst tells investors in a research note. The management’s execution on many aspects of the Carvykti opportunity has been strong, with impressive Overall Survival data, improving real-world safety, expanding manufacturing, and consistent double digit revenue growth, the firm adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech Posts 2025 CARVYKTI Profitability and Tops 10,000 Patients Treated
- Legend Biotech reports Q4 adjusted EPS 1c vs. (15c) last year
- Legend Biotech sees cash runway beyond 2026
- Legend Biotech selloff brings favorable risk/reward, says Deutsche Bank
- LEGN Upcoming Earnings Report: What to Expect?